Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $66
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $62 to $66.
Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $62 to $66.